Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.
Cetin B, Benekli M, Oksuzoglu B, Koral L, Ulas A, Dane F, Turker I, Kaplan MA, Koca D, Boruban C, Yilmaz B, Sevinc A, Berk V, Isıkdogan A, Uncu D, Harputluoglu H, Coskun U, Buyukberber S. Cetin B, et al. Among authors: berk v. Onkologie. 2012;35(12):740-5. doi: 10.1159/000345040. Epub 2012 Oct 31. Onkologie. 2012. PMID: 23207619 Free article.
Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.
Kaya AO, Coskun U, Ozkan M, Sevinc A, Yilmaz AU, Gumus M, Unal OU, Ozdemir NY, Alici S, Berk V, Degerli H, Oner MK, Ozturk C, Kefeli U, Camcı C; Anatolian Society of Medical Oncology (ASMO). Kaya AO, et al. Among authors: berk v. Onkologie. 2012;35(10):576-80. doi: 10.1159/000342674. Epub 2012 Sep 18. Onkologie. 2012. PMID: 23038228
Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N, Benekli M, Koca D, Ustaalioglu BO, Dane F, Ozdemir N, Ulas A, Oztop I, Gumus M, Ozturk MA, Berk V, Kucukoner M, Uner A, Balakan O, Helvaci K, Ozkan S, Yilmaz U, Buyukberber S; Anatolian Society of Medical Oncology. Turan N, et al. Among authors: berk v. Oncology. 2013;84(1):14-21. doi: 10.1159/000342429. Epub 2012 Oct 16. Oncology. 2013. PMID: 23076023
Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
Uncu D, Aksoy S, Çetin B, Yetişyiğit T, Özdemir N, Berk V, Dane F, Inal A, Harputluoğlu H, Budakoğlu B, Koca D, Sevinç A, Cihan S, Durnalı AG, Özkan M, Öztürk MA, Işıkdoğan A, Büyükberber S, Benekli M, Köş T, Alkış N, Karaca H, Turhal NS, Zengin N; Anatolian Society of Medical Oncology. Uncu D, et al. Among authors: berk v. Oncology. 2013;84(4):240-5. doi: 10.1159/000336902. Epub 2013 Feb 7. Oncology. 2013. PMID: 23392240 Clinical Trial.
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Tonyali O, Benekli M, Berk V, Coskun U, Ozkan M, Yildiz R, Ucgul E, Sevinc A, Uncu D, Demirci U, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Tonyali O, et al. Among authors: berk v. J Cancer Res Clin Oncol. 2013 Jun;139(6):981-6. doi: 10.1007/s00432-013-1409-1. Epub 2013 Mar 5. J Cancer Res Clin Oncol. 2013. PMID: 23463098 Clinical Trial.
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Cetin B, Benekli M, Turker I, Koral L, Ulas A, Dane F, Oksuzoglu B, Kaplan MA, Koca D, Boruban C, Yilmaz B, Sevinc A, Berk V, Uncu D, Harputluoglu H, Coskun U, Buyukberber S. Cetin B, et al. Among authors: berk v. J Chemother. 2014 Oct;26(5):300-5. doi: 10.1179/1973947813Y.0000000147. Epub 2013 Dec 6. J Chemother. 2014. PMID: 24112786
73 results